Literature DB >> 22579009

Long term bisphosphonate use in osteoporotic patients; a step forward, two steps back.

Pooneh Salari1, Mohammad Abdollahi.   

Abstract

PURPOSE: Bisphosphonates are the main class of drugs widely used in prevention and treatment of osteoporosis. Along with the beneficial effects, recent studies point to the harms of long-term treatment with bisphosphonates.
METHODS: The most relevant articles reporting serious adverse effects of bisphosphonates were selected and reviewed with the aim of assessing the risk-benefit of bisphosphonates. We searched PubMed, Web of Science, and Scopus using keywords bisphosphonates, risk of fracture, atrial fibrillation, osteonecrosis jaw, esophageal cancer, and adverse effects with no time limitation. We limited our s research to English articles.
RESULTS: Our review shows that bisphosphonates reduce vertebral fractures in short term use while in long-term can cause osteonecrosis jaw, esophageal cancer, atrial fibrillation, and increase the risk of atypical fractures and probably adynamic bone disease. There is no consensus on the time limitation of bisphosphonate usage or its long term adverse effects. Thus, more studies on long-term side effects of bisphosphonates are highly recommended. In addition, new approaches for prevention and treatment of osteoporosis seem necessary.
CONCLUSION: Prescribers should act cautionary and consider full assessment of risk-benefit and the duration of treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22579009     DOI: 10.18433/j3rk5j

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  8 in total

1.  CCR2 elimination in mice results in larger and stronger tibial bones but bone loss is not attenuated following ovariectomy or muscle denervation.

Authors:  Tara L Mader; Susan A Novotny; Angela S Lin; Robert E Guldberg; Dawn A Lowe; Gordon L Warren
Journal:  Calcif Tissue Int       Date:  2014-09-19       Impact factor: 4.333

2.  Ibandronate and ventricular arrhythmia risk.

Authors:  Ingrid M Bonilla; Pedro Vargas-Pinto; Yoshinori Nishijima; Adriana Pedraza-Toscano; Hsiang-Ting Ho; Victor P Long; Andriy E Belevych; Patric Glynn; Mahmoud Houmsse; Troy Rhodes; Raul Weiss; Thomas J Hund; Robert L Hamlin; Sandor Györke; Cynthia A Carnes
Journal:  J Cardiovasc Electrophysiol       Date:  2013-12-20

3.  The influence of pregnancy and lactation on maternal bone health: a systematic review.

Authors:  Pooneh Salari; Mohammad Abdollahi
Journal:  J Family Reprod Health       Date:  2014-12

Review 4.  New horizons in treatment of osteoporosis.

Authors:  Ozra Tabatabaei-Malazy; Pooneh Salari; Patricia Khashayar; Bagher Larijani
Journal:  Daru       Date:  2017-02-07       Impact factor: 3.117

5.  Phosphaturic Mesenchymal Tumor: An Unusual Cause of Stress Fractures Presenting to Sports Medicine.

Authors:  Rafat H Solaiman; Christian M Ogilvie
Journal:  Cureus       Date:  2022-07-14

6.  Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.

Authors:  L Herrera; I Leal; F Lapi; M Schuemie; V Arcoraci; F Cipriani; E Sessa; A Vaccheri; C Piccinni; T Staniscia; A Vestri; M Di Bari; G Corrao; A Zambon; D Gregori; F Carle; M Sturkenboom; G Mazzaglia; G Trifiro
Journal:  Osteoporos Int       Date:  2015-03-10       Impact factor: 4.507

7.  Bisphosphonate Use and Risk of Implant Revision after Total Hip/Knee Arthroplasty: A Meta-Analysis of Observational Studies.

Authors:  Songsong Teng; Chengqing Yi; Christian Krettek; Michael Jagodzinski
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

Review 8.  Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis.

Authors:  Rui Peng; Xingzhong Liang; Gang Zhang; Yuan Yao; Zhen Chen; Xiaojuan Pan; Jinshan Wang; Genglong Liu
Journal:  Biomed Res Int       Date:  2020-10-06       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.